Patents by Inventor Chung-Ming Hsieh

Chung-Ming Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120275996
    Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 1, 2012
    Applicant: ABBOTT LABORATORIES
    Inventor: Chung-ming Hsieh
  • Publication number: 20120237976
    Abstract: The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies.
    Type: Application
    Filed: February 8, 2012
    Publication date: September 20, 2012
    Applicant: ABBOTT LABORATORIES
    Inventor: Chung-ming HSIEH
  • Publication number: 20120230911
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: December 8, 2011
    Publication date: September 13, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Chung-ming HSIEH, Carrie L. GOOGREAU, Sahana BOSE, Achim MOELLER, Tariq GHAYUR
  • Patent number: 8187836
    Abstract: The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: May 29, 2012
    Assignee: Abbott Laboratories
    Inventor: Chung-ming Hsieh
  • Publication number: 20120091976
    Abstract: A bootstrap circuit without a regulator and a diode includes a comparator, a first switch, and a capacitor. The comparator has a first terminal for receiving a reference voltage, a second terminal coupled to a bootstrap voltage output terminal of the bootstrap circuit, and a third terminal for outputting a switch control signal. The first switch has a first terminal for receiving an input voltage, a second terminal for receiving the switch control signal, and a third terminal coupled to the bootstrap voltage output terminal. The capacitor is coupled between a voltage switching terminal and the second terminal of the comparator.
    Type: Application
    Filed: November 25, 2010
    Publication date: April 19, 2012
    Inventors: Chi-Ming Chen, Chung-Ming Hsieh
  • Publication number: 20110280800
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Application
    Filed: May 13, 2011
    Publication date: November 17, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Chengbin WU, Tariq GHAYUR, Chung-ming HSIEH, Dominic J. AMBROSI
  • Publication number: 20110223176
    Abstract: Isolated binding proteins, e.g., antibodies, which bind to Basigin (BSG), e.g., human BSG2, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Eve H. Barlow, Chung-Ming Hsieh, Denise D. Karaoglu Hanzatian, Gillian Ann Kingsbury, Susan E. Morgan-Lappe, Edward B. Reilly, Fritz G. Buchanan, Yingchun Li
  • Publication number: 20110217237
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 8, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • Publication number: 20110165063
    Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.
    Type: Application
    Filed: October 21, 2010
    Publication date: July 7, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Chung-ming HSIEH, Chengbin WU
  • Publication number: 20110142761
    Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.
    Type: Application
    Filed: October 15, 2010
    Publication date: June 16, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Chengbin Wu, Chung-ming Hsieh, Renee Miller, Dominic J. Ambrosi
  • Publication number: 20110117079
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Application
    Filed: August 27, 2010
    Publication date: May 19, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Publication number: 20100279280
    Abstract: The invention provides methods and reagents for detecting a polymorphism associated with in an upstream region of the interleukin-1 beta (IL-B) gene (IL-1B (?3737)) that affects transcription of the gene and susceptibility to inflammatory and infectious diseases such as periodontal disease and Alzheimer's disease.
    Type: Application
    Filed: March 13, 2008
    Publication date: November 4, 2010
    Inventors: David Wyllie, Gordon Duff, Nazneen Aziz, Chung-Ming Hsieh, Kenneth Kornman
  • Publication number: 20100266531
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Application
    Filed: March 5, 2010
    Publication date: October 21, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: CHUNG-MING HSIEH, MARGARET HUGUNIN, ANWAR MURTAZA, BRADFORD L. MCRAE, YULIYA KUTSKOVA, JOHN E. MEMMOTT, JENNIFER M. PEREZ, SUJU ZHONG, EDIT TARCSA, ANCA CLABBERS, CRAIG WALLACE, SHAUGHN H. BRYANT, MARY R. LEDDY
  • Publication number: 20100221179
    Abstract: The present invention encompasses IL-1? binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1? and neutralize IL-1? activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, e.g., in a human subject suffering from a disorder in which IL-1? activity is detrimental.
    Type: Application
    Filed: January 29, 2010
    Publication date: September 2, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Chung-ming Hsieh, Chengbin Wu
  • Publication number: 20100105569
    Abstract: The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.
    Type: Application
    Filed: September 30, 2009
    Publication date: April 29, 2010
    Applicant: Abbott Laboratories
    Inventors: Chung-Ming Hsieh, Yuliya A. Kutskova, John E. Memmott
  • Publication number: 20100099103
    Abstract: The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.
    Type: Application
    Filed: September 30, 2009
    Publication date: April 22, 2010
    Applicant: Abbott Laboratories
    Inventors: Chung-Ming Hsieh, Yuliya A. Kutskova, John E. Memmott
  • Publication number: 20100040537
    Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
    Type: Application
    Filed: July 8, 2009
    Publication date: February 18, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Jjijie Gu, Charles W. Hutchins, Rong-rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Anwar Murtaza, Edit Tarcsa, William B. Stine, Chung-ming Hsieh
  • Publication number: 20100028359
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products.
    Type: Application
    Filed: May 8, 2009
    Publication date: February 4, 2010
    Applicants: ABBOTT GMBH & CO. KG, ABBOTT LABORATORIES
    Inventors: Jijie GU, Chung-Ming HSIEH, Zhen WU, Enrico L. DiGIAMMARINO, Feng LUO, Gerard B. FOX, John E. HARLAN, Martin SCHMIDT, Ralf LOEBBERT, Reinhold MUELLER, Ulrich EBERT, Volker NIMMRICH
  • Publication number: 20100028340
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
    Type: Application
    Filed: February 20, 2009
    Publication date: February 4, 2010
    Applicants: Abbott GmbH & Co. KG, Abbott Laboratories
    Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
  • Publication number: 20090291081
    Abstract: The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1? and human IL-1?. The dual specific antibodies of the invention also neutralize both human IL-1? and human IL-1?. The invention also provides domain antibodies (dAbs) specific for human IL-1? and human IL-1?.
    Type: Application
    Filed: December 28, 2007
    Publication date: November 26, 2009
    Inventors: Chung-Ming Hsieh, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Michael Roguska, Ian Tomlinson, Carrie Enever, Steven Grant, Mihriban Tuna